Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus LR607
- Development stage
- Phase 2
- Lead developer
- H&H Group
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Lactobacillus rhamnosus* LR607 is a specific probiotic strain belonging to the *Lactobacillaceae* family, extensively utilized in the development of pediatric nutritional supplements and live biotherapeutic products. Developed by the H&H Group (Biostime), LR607 is characterized by its ability to survive transit through the gastrointestinal tract and adhere to intestinal epithelial cells. Its mechanism of action involves the modulation of the host's innate and adaptive immune responses, enhancement of the intestinal mucosal barrier, and competitive exclusion of enteric pathogens. Clinical investigations have primarily focused on its role in reducing the frequency and severity of common respiratory tract infections (RTIs) and gastrointestinal distress in infants and young children. By influencing the composition and metabolic activity of the gut microbiota, LR607 promotes a balanced microbial environment conducive to overall health and immune resilience.
- Brand names
- Biostime
- Other names
- Lacticaseibacillus rhamnosus LR607L. rhamnosus LR607
Beyond the preview
Go deeper on lactobacillus rhamnosus LR607.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus LR607.